CNSP Stock Summary and Trading Ideas (CNS Pharmaceuticals | NASDAQ:CNSP)

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

CNS Pharmaceuticals trades on the NASDAQ stock market under the symbol CNSP.

As of February 28, 2025, CNSP stock price climbed to $2.43 with 200,177 million shares trading.

CNSP has a market cap of $3.64 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CNSP traded as high as $41,250.41 and as low as $2.24.

The top ETF exchange traded funds that CNSP belongs to (by Net Assets): VXF.

CNSP has underperformed the market in the last year with a price return of -99.6% while the SPY ETF gained +18.8%. CNSP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -57.9% and -65.3%, respectively, while the SPY returned -0.4% and -2.5%, respectively.

CNSP support price is $2.01 and resistance is $2.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNSP shares will trade within this expected range on the day.